Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of ...

Preanalytical errors in clinical labs—like hemolysis, contamination, or mislabeling—can derail patient care before testing even begins. These mistakes are most common in high-pressure areas like ...

Fulcrum Therapeutics (NASDAQ:FULC) highlighted new clinical and corporate progress during its first-quarter 2026 financial results and business update call, with management emphasizing positive Phase ...

A novel pulsed field ablation technology was safe and prevented atrial arrhythmia recurrence in most patients with paroxysmal ...

Light-driven antioxidant nanomotors help reach injured kidney tissue and reduce the damage that allows kidney stone crystals ...

Beam Therapeutics Inc. (NASDAQ:BEAM) is one of the 10 best biotech stocks with highest upside potential. On April 2, Beam ...

CellFX marks another route for Afib ablation technology ...

Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusi ...

In this MedPage Today video, Nikki B. Zite, MD, MPH, of the University of Tennessee Medical Center in Knoxville, breaks down ...

Non-tobacco nicotine use before a positive pregnancy result increased the risk for pregnancy and delivery complications, ...

Treatment success with pulsed field ablation was higher at 1 year than with antiarrhythmic drug therapy for patients with persistent atrial fibrillation.

Presented positive clinical data for pociredir, demonstrating robust and rapid fetal hemoglobin (HbF) induction, improvements in markers of hemolysis and anemia, and encouraging trends in vaso-occlusi ...